• W Christopher Newman, Mark H Bilsky, and Ori Barzilai.
• Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
• Neurosurgery. 2025 Mar 1; 96 (3S): S119S128S119-S128.

AbstractThe application of minimally invasive spine surgery (MISS) in degenerative spine disease and deformity has seen rapid growth in the past 20 years. Building on this experience, such methods have been adopted into spine oncology in the past decade, particularly for metastatic disease. The impetus for this growth stems from the benefits of surgical decompression combined with radiation treatment in patients with metastatic disease in conjunction with the need for less morbid interventions in a patient population with limited life expectancy. The result of these two realizations was the application of minimally invasive techniques for the treatment of spine tumors including re-establishment of spinal stability, decompression of the spinal cord or nerve roots, and restoration of spinal alignment. Technological advancement and improvement in biomaterials have allowed for durable stabilization with short constructs even for patients with poor bone quality. The implementation of navigation and robotic capabilities has transformed MISS by streamlining surgery and further reducing the surgical footprint while laser ablation, endoscopy, and robotic surgery hold the potential to minimize the surgical footprint even further. MISS for intradural tumors is commonly performed, while the role for other primary tumors has yet to be defined. In this article, we describe the evolution of and indications for MISS in spine oncology through a retrospective literature review.Copyright © Congress of Neurological Surgeons 2025. All rights reserved.

15 keywords...

hide…